With over a decade of cannabis reform advocacy with the National Organization for the Reform of Marijuana Laws (NORML), Bailey was Washington NORML’s Legislative Associate during the 2017-18 legislative sessions and the only lobbyist focused solely on recreational cannabis policy. He’s currently the consumer representative on the Washington State Liquor and Cannabis Board’s Cannabis Advisory Council and consults for regulators, licensees, and individuals. Bailey has a Bachelor of Arts in Interdisciplinary Studies from the University of Missouri-Columbia, and lives in Lacey, Washington with his wife.
The Board reviewed open agency rulemaking projects and learned new information about WSDA’s prospective organic-equivalent Certified Cannabis program.
Senators heard and moved both WSLCB agency request bills, HB 2826 on marijuana vapor products and HB 2870 on social equity in the cannabis industry.
The City hosted a town hall format event to gather feedback from communities impacted by the war on drugs while providing details on municipal and state equity efforts including HB 2870.
On Tuesday, Senators passed three cannabis-related bills late in the evening on the day before the house of origin cutoff: SB 6057, SB 6206, and SB 5867. All proceed to the House.
Agency leadership heard a briefing on cannabis-related legislation still active and otherwise, including both agency requests and bills introduced by other stakeholders.
The Board denied three petitions for rulemaking and discussed HB 2870, an agency request bill to create a social equity program which has been substantially modified by legislators.
The committee heard the cannabis commodity commission bill and passed WSLCB’s request legislation to expand agency rulemaking power and DOH authority over marijuana products.
The fiscal committee heard substantial positive testimony on HB 1131, the home grow bill, and has until this coming Tuesday to refer it out of committee to continue its momentum.
The Board superseded its emergency rules on vitamin E acetate in vapor products then heard concerns about ingredient disclosure forms and truth in agency messaging.
The Board heard a substantial review of the agency’s program with WSDA for cannabis product testing and prepared to revise emergency rules on vapor products.